Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.66+1.83%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DARE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -11.4% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
DARE — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-10-02
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 28, 2026, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Na…
Why it matters: Flora Sync LF5 launched in July. Sales growth would test demand for the company's first direct-to-consumer product.
Supportive ifThe Nov. 12 report shows Flora Sync LF5 sales above the first reported revenue from July.
Worry ifThe Nov. 12 report shows no Flora Sync LF5 sales, or sales below the first reported revenue from July.
Why it matters: Nasdaq notified Daré that its bid price stayed below $1.00 for 30 business days. Regaining the rule would address this listing risk.
Supportive ifA company filing says the stock closed at $1.00 or more for 10 business days in a row during Nasdaq's cure period.
Worry ifA company filing says the stock did not close at $1.00 or more for 10 business days in a row during Nasdaq's cure period.
Why it matters: Ovaprene's next key test is completing enough study cycles for its main analysis. Meeting the stated timeline would keep the program moving.
Supportive ifDaré reports at least 2,500 study cycles in 2026 and keeps the main Phase 3 analysis on track for 2027.
Worry ifDaré reports fewer than 2,500 study cycles by year-end 2026 or moves the main analysis past 2027.
Why it matters: The study began with a target of about 100 women. Enrollment and results will test whether the program stays on its stated path.
Supportive ifDaré reports enrollment near 100 women and keeps topline results on track for 2027.
Worry ifDaré reports enrollment well below 100 women or delays topline results beyond 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$244 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $845 loss on $10,000 · 8.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,031 loss on $10,000 · 80.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.